Frank Pallone actually said...
I worry that this inappropriately treats biosimilars like generic drugs and will disincentivize manufacturers from entering the biosimilars marketplace.
Context
Pallone expresses concern over CMS's payment policy for biosimilars affecting market entry.
02/03/2016